A randomised controlled trial of gemcitabine hydrochloride plus S-1 combination therapy versus gemcitabine hydrochloride therapy alone in pancreatic cancer patients aged ≥75 years: a study protocol for an open-label randomised feasibility study

INTRODUCTION: In Japan, the age of patients with pancreatic cancer has increased. Combination chemotherapies such as 5-fluorouracil/leucovorin, oxaliplatin and irinotecan therapy and gemcitabine hydrochloride (GEM) +nab paclitaxel therapy have been developed as the standard treatments for young pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishii, Hiroshi, Yamashita, Natsumi, Ueno, Makoto, Ohkawa, Shinichi, Saito, Akiko M, Sekimoto, Mitsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Pancreatic Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5841525/
https://www.ncbi.nlm.nih.gov/pubmed/29527313
http://dx.doi.org/10.1136/bmjgast-2017-000187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5841525/
https://www.ncbi.nlm.nih.gov/pubmed/29527313
http://dx.doi.org/10.1136/bmjgast-2017-000187

Ejemplares similares